Breast Cancer Research

official impact factor 5.79
Search for
Advanced search
Breast Cancer Research
Tools
Share this article
Open Access Highly Access Research article

Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours

Jill E Kucab1, Cathy Lee1, Ching-Shih Chen2, Jiuxiang Zhu2, C Blake Gilks3, Maggie Cheang3, David Huntsman3, Erika Yorida3, Joanne Emerman4, Michael Pollak5 and Sandra E Dunn1*

Author Affiliations

1 British Columbia Research Institute for Children's and Women's Health, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada

2 Division of Medical Chemistry and Pharmacognosy, The Ohio State University, Columbus, Ohio, USA

3 Genetic Pathology Evaluation Centre, Vancouver Hospital and Health Sciences Centre and BC Cancer Agency, Vancouver, British Columbia, Canada

4 Department of Anatomy, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

5 Division of Experimental Medicine, Department of Medicine and Department of Oncology, McGill University, Montreal, Quebec

For all author emails, please log on.

Breast Cancer Research 2005, 7:R796-R807 doi:10.1186/bcr1294


Please see related commentary by Crowder and Ellis at: http://breast-cancer-research.com/content/7/5/212

Published: 1 August 2005

Additional files

Additional File 1:

A table summarizing the characteristics of the patients and their tumours.

Format: PDF Size: 7KB Download file

This file can be viewed with: Adobe Acrobat Reader

Open Data